Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 401

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

Open access
Gemenetzis, Georgios, Groot, Vincent P., Blair, Alex B., Laheru, Daniel A., Zheng, Lei, Narang, Amol K., Fishman, Elliot K., Hruban, Ralph H., Yu, Jun, Burkhart, Richard A., Cameron, John L., Weiss, Matthew J., Wolfgang, Christopher L., He, Jin·2019·Annals of Surgery

Abstract

Objective: The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes. Background: An increasing number of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection. The impact of surgery on patient survival is largely unknown. Materials and Methods: All LAPC patients who presented to the institutional pancreatic multidisciplinary clinic (PMDC) from January 2013 to September 2017 were included in the study. Demographics and clinical data on neoadjuvant treatment and surgical resection were documented. Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the primary study endpoints. Results: A total of 415 LAPC patients were included in the study. Stratification of neoadjuvant therapy in FOLFIRINOX-based, gemcitabine-based, and combination of the two, and subsequent outcome comparison did not demonstrate significant differences in OS of 331 non-resected LAPC patients (P = 0.134). Eighty-four patients underwent resection of the primary tumor (20%), after a median duration of 5 months of neoadjuvant therapy. FOLFIRINOX-based therapy and stereotactic body radiation therapy correlated with increased probability of resection (P = 0.006). Resected patients had better performance status, smaller median tumor size (P = 0.029), and lower median CA19-9 values (P < 0.001) at PMDC. Patients who underwent surgical resection had significant higher median OS compared with those who did not (35.3 vs 16.3 mo, P < 0.001). The difference remained significant when non-resected patients were matched for time of neoadjuvant therapy (19.9 mo, P < 0.001). Conclusions: Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected cohort of patients (20%) and is associated with significantly longer median overall survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000002753

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 401

Metadata

Authors
Gemenetzis, G., Groot, V. P., Blair, A. B., Laheru, D. A., Zheng, L., Narang, A. K., Fishman, E. K., Hruban, R. H., Yu, J., Burkhart, R. A., Cameron, J. L., Weiss, M. J., Wolfgang, C. L., & He, J.
Venue
Annals of Surgery
Published
2019-08
Volume
270
Issue
2
Pages
340-347
ISSN
  • 0003-4932 (ISSN-L)
  • 1528-1140
OpenAlex
W2801301689
Cited by
401
References
33
FWCI
13.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. https://app.cochat.ai/papers/10.1097/sla.0000000000002753
The paper
Gemenetzis, G., Groot, V. P., Blair, A. B., Laheru, D. A., Zheng, L., Narang, A. K., Fishman, E. K., Hruban, R. H., Yu, J., Burkhart, R. A., Cameron, J. L., Weiss, M. J., Wolfgang, C. L., & He, J. (2019). Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery. https://doi.org/10.1097/sla.0000000000002753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.